<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(2)</volume><submitter>Odling M</submitter><funding>Mjölkdroppen Foundation</funding><funding>The Swedish Association for Allergology</funding><funding>Sachs's Children and Youth Hospital</funding><funding>Konsul Th C Bergh's Foundation</funding><funding>Svenska Föreningen för Allergologi</funding><funding>Hesselman's Foundation</funding><funding>Her Royal Highness Crown Princess Lovisa's research fund</funding><funding>Astma- och Allergiförbundet</funding><funding>Region Stockholm (ALF-project)</funding><funding>the Swedish Asthma and Allergy Association</funding><funding>Torsten Söderbergs's Foundation</funding><journal>Clinical and translational allergy</journal><pagination>e12225</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9899491</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Peanut oral immunotherapy may improve health-related quality of life among severe peanut allergic adolescents.</pubmed_title><pmcid>PMC9899491</pmcid><pubmed_authors>Sundqvist AC</pubmed_authors><pubmed_authors>Nopp A</pubmed_authors><pubmed_authors>Odling M</pubmed_authors><pubmed_authors>Brandstrom J</pubmed_authors><pubmed_authors>Kull I</pubmed_authors><pubmed_authors>Andersson N</pubmed_authors><pubmed_authors>Nilsson C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Peanut oral immunotherapy may improve health-related quality of life among severe peanut allergic adolescents.</name><description/><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-22T11:13:30.473Z</modification><creation>2025-04-05T23:50:08.659Z</creation></dates><accession>S-EPMC9899491</accession><cross_references><pubmed>36825514</pubmed><doi>10.1002/clt2.12225</doi></cross_references></HashMap>